Compare AbCellera Biologics Inc (ABCL) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Johnson Controls International PLC — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Johnson Controls International PLC trades at $140 (market cap $85.79B). The key difference: Johnson Controls International PLC is far larger — about 36.5× AbCellera Biologics Inc's market cap, and Johnson Controls International PLC pays a 1.14% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | JCI | |
|---|---|---|
Market Cap | $2.35B | $85.79B |
Sector | Health | Industrials |
52-Week High | $8.12 | $148.21 |
52-Week Low | $2.78 | $103.24 |
Enterprise Value | $1.99B | $94.62B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Johnson Controls International (JCI) trades at $140.62, down 0.1% on the day, with strong analyst support showing 62% buy ratings and a consensus price target of $153.67. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.19 surpassing the $1.12 estimate. The company maintains solid profitability with a 14.45% net income margin and recently announced a $0.40 dividend payable in July 2026. Technical indicators show a bullish trend with support at $139 and resistance at $145.
JCI presents a favorable investment case with earnings momentum, strong analyst conviction, and exposure to growing markets like data center cooling. Key risks include elevated valuation multiples (P/E of 43.65) and increasing debt-to-asset ratios. The stock's current price offers approximately 9% upside to consensus targets, though investors should monitor execution on revenue growth projections and competitive pressures in the building solutions sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
